Literature DB >> 7749683

Cyclin/proliferation cell nuclear antigen immunohistochemistry does not improve the prognostic power of Dukes' or Jass' classifications for colorectal cancer.

J P Neoptolemos1, G D Oates, K M Newbold, A M Robson, C McConkey, J Powell.   

Abstract

Immunohistochemistry of cyclin/proliferation cell nuclear antigen (PCNA) is an attractive alternative to tumour cell proliferation activity determined by flow cytometry which has been shown to be independently predictive of survival in patients with colorectal carcinoma and to enhance Dukes' classification. Dukes' and Jass' histopathological classifications were determined in 91 patients who had undergone curative resection for cancer of the colon (n = 51) or rectum (n = 40) and followed up for a minimum of 10 years. PCNA immunohistochemistry was possible in 79 tumours. Univariate analysis revealed that Jass' (P < 0.0001) and Dukes' classifications (P < 0.0002) were powerful predictors of survival but that the PCNA index had little prognostic power (P = 0.4). Multivariate analysis of both classifications showed similar predictive power and the PCNA index improved the prediction of survival when used with either classification for patients with colon cancer (chi 2 = 5.3, 1 d.f., P = 0.02 for each combination). The PCNA index, however, was not predictive for rectal cancer. Patients with the lowest PCNA index had the worst prognosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7749683     DOI: 10.1002/bjs.1800820214

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  5 in total

1.  Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers.

Authors:  Jun-Jie Peng; San-Jun Cai; Hong-Feng Lu; Guo-Xiang Cai; Peng Lian; Zu-Qing Guan; Ming-He Wang; Ye Xu
Journal:  World J Gastroenterol       Date:  2007-06-07       Impact factor: 5.742

2.  Association between histological type of tumour growth and patient survival in t2-t3 lymph node-negative rectal cancer treated with sphincter-preserving total mesorectal excision.

Authors:  Bartlomiej Szynglarewicz; Rafal Matkowski; Agnieszka Halon; Aleksandra Lacko; Marcin Stepien; Jozef Forgacz; Marek Pudelko; Jan Kornafel
Journal:  Pathol Oncol Res       Date:  2009-09-15       Impact factor: 3.201

3.  Tumour markers of prognosis in colorectal cancer.

Authors:  H L McLeod; G I Murray
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

4.  Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers.

Authors:  R Palmqvist; P Sellberg; A Oberg; B Tavelin; J N Rutegård; R Stenling
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

5.  The prognostic value of proliferating cell nuclear antigen expression in colorectal cancer: A meta-analysis.

Authors:  He Zhou; Tao Huang; Yongfu Xiong; Linglong Peng; Rong Wang; Guang Jun Zhang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.